Publicacións en colaboración con investigadores/as de Dalhousie University (9)

2024

  1. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

  2. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107

2023

  1. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

2021

  1. Association of Rare CYP39A1 Variants with Exfoliation Syndrome Involving the Anterior Chamber of the Eye

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 8, pp. 753-764

  2. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

    Vaccine, Vol. 39, Núm. 11, pp. 1598-1608

2020

  1. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial

    Vaccine, Vol. 38, Núm. 8, pp. 2095-2104

  2. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial

    Vaccine, Vol. 38, Núm. 8, pp. 2105-2114

2017

  1. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci

    Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004

2016

  1. Meeting report: Harmonization of RSV therapeutics - from design to performance

    Journal of Global Health, Vol. 6, Núm. 1